Table 2.

Comparison of overall response rate between biosimilar and reference groups.

	biosimilar group (n=551)	reference group (n=395)
Best overall response, n (%)
PR	159 (28.9%)	122 (30.9%)
SD	334 (60.6%)	223 (56.4%)
PD	58 (10.5%)	50 (12.7%)
ORR	28.9%	30.9%
95% exact CI	25.1%-32.7%	26.3%-35.5%
Treatment comparison (vs referrence bevacizumab group)
Unstratified ORR risk ratio	0.934
95% CI of risk ratio	0.767-1.138
90% CI of risk ratio	0.792-1.103
Unstratified ORR risk difference	-0.020
95% CI of difference	-0.118-0.035
90% CI of difference	-0.105-0.023

ORR, overall/objective response rate; PR, partial response; SD, stable disease; PD, progressive disease.